1. Introduction {#sec1-cancers-12-02184}
===============

High-grade serous ovarian cancers (HGSOC) are heterogeneous \[[@B1-cancers-12-02184]\] and lack specific clinical signs and efficient screening \[[@B2-cancers-12-02184]\]. They are often diagnosed at an advanced stage and associated with poor survival rates, i.e., 39% of the five-year overall survival (OS) rate \[[@B3-cancers-12-02184]\]. According the French Registry, the probability of OS at five years reaches 41% for patients treated for ovarian cancer in the 1989--2010 period \[[@B4-cancers-12-02184]\]. The current therapeutic strategy combines maximal cytoreductive surgery and platinum-based chemotherapy \[[@B5-cancers-12-02184],[@B6-cancers-12-02184]\]. Despite an initial sensitivity to cytostatic drugs, 75% of patients eventually relapse at 12--18 months \[[@B3-cancers-12-02184],[@B5-cancers-12-02184],[@B7-cancers-12-02184]\]. The clinical prognostic factors associated with OS included age, stage (I--II vs. III--IV) performance status, and low-grade histology. The role of the residual disease after surgery remains essential for impacting the future of the patients who could be operated \[[@B8-cancers-12-02184],[@B9-cancers-12-02184]\]. More recently, for patients who are not eligible for initial macroscopic complete resection and treated with neoadjuvant chemotherapy, the addition of hyperthermic intraperitoneal chemotherapy has demonstrated a 12-month increase in OS \[[@B10-cancers-12-02184]\]. As biological prognostic factors, the perioperative kinetics of CA 125 has been found to influence the OS \[[@B11-cancers-12-02184]\]. Moreover, patients with BRCA mutations have been shown to survive longer than others and harbor higher intrinsic platinum sensitivity \[[@B12-cancers-12-02184]\], although, for other authors, BRCA mutations alone cannot explain the long-term survival \[[@B13-cancers-12-02184]\].

For HGSOC patients, death usually occurs within 36 to 50 months after diagnosis \[[@B7-cancers-12-02184]\]. Around 15% to 20% of patients are considered long-term survivors (LTS) once they have survived more than five or six years after diagnosis, even considering the advanced stage of disease \[[@B12-cancers-12-02184],[@B14-cancers-12-02184]\]. The definition of LTS varies regarding staging, grading, histology, and biology \[[@B15-cancers-12-02184]\]. Since the median of survival reaches around 50 months, the vast majority of the authors consider LTS beyond this median. We choose 60 months in order to observe a clear decrease of the probability to die of the disease \[[@B15-cancers-12-02184]\]. Regardless of the surgical or oncologic treatments they have received, this specific LTS population is expected to harbor particular biological characteristics such as germline or somatic homologous recombination deficiency.

The prognosis factors of LTS are not clearly defined, although these are needed in clinical practice both for clinicians and patients. Published prognostic factors for patients' survival provide essential information for estimating their survival rate at diagnosis. However, for patients who survive more than five years without a relapse, these factors are less instructive for evaluating the likelihood of a late recurrence and death from the disease. The evolution of ovarian cancer is often described in terms of survival rates, calculated from the date of cancer diagnosis and estimated by the Kaplan-Meier method. For those patients who have already survived a period of time after diagnosis, the question is whether their life expectancy can be readjusted considering their already quite long survival. Moreover, as death events occur in a nonlinear model, readjusting the probability of survival according to the already survived interval from diagnosis is justified. The conditional probability of survival, i.e., the probability of survival for a patient who has already survived a period of time after diagnosis and treatment, offers these patients more accurate and relevant information. This has been assessed for many different cancer sites (lung \[[@B16-cancers-12-02184],[@B17-cancers-12-02184]\], digestive system \[[@B18-cancers-12-02184],[@B19-cancers-12-02184],[@B20-cancers-12-02184]\], brain \[[@B21-cancers-12-02184]\], head and neck cancers \[[@B22-cancers-12-02184]\], and melanomas \[[@B23-cancers-12-02184],[@B24-cancers-12-02184]\]) and, also, in studies using data from the SEER (Surveillance, Epidemiology and End Results) database \[[@B25-cancers-12-02184],[@B26-cancers-12-02184],[@B27-cancers-12-02184]\].

Two studies assessed \[[@B14-cancers-12-02184],[@B25-cancers-12-02184]\] the conditional survival in patients with ovarian cancer, showing that conditional survival was a more accurate estimation than an estimation made at the time of diagnosis (conventional survival estimation). For a given already survived period of time, the probability of surviving longer increases compared with the initial probability at diagnosis, especially for patients with serous and poorly differentiated tumors. However, these studies did not assess all demographic and new biological tumor factors. Indeed, the standards of care in ovarian cancer have evolved, especially with the incorporation of poly(ADP-ribose) polymérase (PARP) inhibitors for maintenance therapy as a first line of treatment or for recurrence \[[@B28-cancers-12-02184],[@B29-cancers-12-02184],[@B30-cancers-12-02184],[@B31-cancers-12-02184],[@B32-cancers-12-02184],[@B33-cancers-12-02184],[@B34-cancers-12-02184]\].

In this context, we conducted a retrospective study of HGSOC LTS patients, i.e., patients who had already survived five years after diagnosis, to estimate the conditional probability of their survival and identify the prognostic factors of the OS.

2. Results {#sec2-cancers-12-02184}
==========

2.1. Patients {#sec2dot1-cancers-12-02184}
-------------

Among the 553 patients recorded in the ovarian cancer database, 404 were analyzed in the study, including 120 patients (29.7%) considered as long-term survivors (LTS) ([Table 1](#cancers-12-02184-t001){ref-type="table"}). The median age at diagnosis was 57 years (range: 21--83) for LTS and 62 years (range: 20--89) for the non-LTS. More patients were younger at diagnosis (\<65 years old) among LTS than among the non-LTS (75.8% vs. 59.2%, *p* \< 0.001). The WHO performance status was 0 to 1 and 2 in 92.5% and 7.5% of the LTS group and 84.7% and 15.3% of the non-LTS group (*p* = 0.045). CA 125 levels and staging at the baseline did not differ for either group. Overall, most patients (82.7%) had a FIGO stage III tumor and 17.3% FIGO stage IV. In the whole population, 32.3% of patients presented visceral metastases. BRCA status was available for 28.7% of all patients. Among them, BRCA 1 and 2 genes were mutated in 36.2% of LTS and in 29.3% of non-LTS, which was not significantly different between the two groups.

2.2. Treatment {#sec2dot2-cancers-12-02184}
--------------

Primary debulking surgery was performed in 67.5% and 46.8% in the LTS and non-LTS groups (*p* \< 0.001) ([Table 2](#cancers-12-02184-t002){ref-type="table"}). Macroscopic residual disease was null for 63.3% of LTS and 56.3% of non-LTS. A peritoneal carcinomatosis index (PCI) \> 17 was reported in 17.9% of LTS vs. 37.0% in the non-LTS group (*p* \< 0.001). Neoadjuvant chemotherapy was administered to 31.1% of LTS and 51.9% of the non-LTS (*p* \< 0.001), with a median number of cycles of six (range: 1--14) for both groups. Eighty percent of patients were treated with first-line platinum-based chemotherapy plus paclitaxel. Primary platinum sensitivity of the tumors was reported more frequently in the LTS group, with 95% in the LTS group and 68% in the non-LTS group (*p* = 0.001). A treatment-free interval (TFI) ≥ 18 months was reported for 57.8% and 14.4% of patients in the LTS and non-LTS groups (*p* \< 0.001), and a progression-free interval (PFI) ≥ 18 months was reported in 85.8% and 33.5% of patients, respectively (*p* \< 0.001).

2.3. Survival and Conditional Survival {#sec2dot3-cancers-12-02184}
--------------------------------------

After a median follow-up of nine point three years (range: 0.15--20.8), the median OS for the whole population was four years (95% CI: 3.6--4.5), and the median relapse-free survival was one point sixyears (95% CI: 1.5--1.8). The CPS at five years after surviving one year after diagnosis was 42.8% (95% CI: 35.3--48.3), and it increased up to 50.9% (95% CI: 44.8--57.0), 62% (95% CI: 55.4--68.7), and 81.7% (95% CI: 75.5--87.8) after surviving two, three, and four years, respectively ([Table 3](#cancers-12-02184-t003){ref-type="table"}). Conditional survival at five years and the CPS for one additional year according to the time since diagnosis are reported in [Figure 1](#cancers-12-02184-f001){ref-type="fig"}a,b. [Figure 1](#cancers-12-02184-f001){ref-type="fig"}b shows *n +* oneyear CPS estimates for patients who have already survived *n* years, in which *n* varies from zero to six. CPS for one additional year decreases until four years after diagnosis, then seems to stabilize subsequently.

2.4. Prognostic Factors of Long-Term Survival According to the Five-Year Landmark Analysis {#sec2dot4-cancers-12-02184}
------------------------------------------------------------------------------------------

Prognostic factors for LTS were assessed using the Landmark analysis at five years in a univariate analysis. Age \< 65 years, complete surgery, initial PCI ≤ 17, and PFI ≥ 18 months were found to be significant factors associated with a good prognosis ([Table 4](#cancers-12-02184-t004){ref-type="table"}). In the multivariate analysis, only the progression-free interval was found to be significant (HR = 0.23; 95% CI: 0.13--0.40; *p* \< 0.001).

3. Discussion {#sec3-cancers-12-02184}
=============

In our population of HGSOC patients, the probability of surviving after having already survived a given time after diagnosis increased in the first two to three years after diagnosis, then stabilized from the fifth year and beyond. We showed that the probability of surviving one additional year after four years post-diagnosis was 81.7% (95% CI: 75.5; 87.8), while the classical five-year OS was 40.6% (95% CI: 35.3; 45.9). The CPS for one additional year first decreased, then seemed to stabilize after four years, suggesting a more optimistic future. Our results confirm that CPS is a precious tool for physicians to use during their patients′ follow-ups and to inform them of their life expectancy. It is indeed one of the greatest expectations from patients to hear probable survival figures, allowing them to make projects more easily in their personal or professional lives.

Two previous studies analyzed the CPS in ovarian cancer patients. A first study from the SEER database showed that, in patients treated between 1988 and 2001, the five-year OS improved in patients who had already survived five years \[[@B25-cancers-12-02184]\]. However, these results are to be read with caution, as standards of practice have evolved since then, especially with the development of platinum-based and taxane-based chemotherapies. The prognosis is now better than at the time of that study. Another study confirmed these data on CPS. They showed that, in Stage I to IV ovarian cancer patients, the conditional disease-free survival increased over time, even in patients with an initial high risk of recurrence \[[@B14-cancers-12-02184]\]. However, this study included a fairly heterogeneous population compared with other studies (including ours, because our patients were only Stage III-IV HGSOC). Their endpoint was to study CPS based on PFS, unlike OS in ours. The median OS was four point five years and four years in Kurta's study and our study, respectively. It is notable that, at that period of time, our population was not receiving any maintenance treatment with a significant impact, such as PARP inhibitors. Despite this fact, we wish to point out the heterogeneity of high-stage HGSOC behaviors beyond macroscopic complete resection.

The second objective of our study was to identify additional prognostic factors of long-term survival, especially biological parameters that might characterize subgroups of LTS. Our results in the univariate analysis were in accordance with the standard prognostic factors usually reported, i.e., age, absence of a macroscopic residual disease after primary or interval cytoreductive surgery, and the extent of peritoneal disease (PCI) \[[@B8-cancers-12-02184],[@B9-cancers-12-02184],[@B34-cancers-12-02184],[@B35-cancers-12-02184],[@B36-cancers-12-02184]\]. In previous studies, many attempts to identify a PCI threshold as a prognostic factor have been performed. The scores vary between 13 to 17 \[[@B37-cancers-12-02184],[@B38-cancers-12-02184]\]. We choose 17 as the cutoff according to what was published in colorectal and ovarian carcinomatosis. In an attempt to definitively sterilize macroscopic disease, intraperitoneal chemotherapy has been used after primary debulking surgery or HIPEC in interval surgery, with results to be confirmed.

In the multivariate analysis, only the PFI was found to be a prognostic factor for LTS; having survived more than 18 months between the first line of chemotherapy and the date of recurrence was considered to favorably impact the OS with a hazard ratio reaching 0.23 (95% CI: 0.13--0.40) in a Landmark analysis at five years. In other terms, the longer the disease is controlled, the greater the likelihood of a definitive cure. This effect has also been reported for other high-grade malignant diseases \[[@B21-cancers-12-02184]\].

Sensitivity of the disease to platinum compounds, defined as a delay in recurrence of more than six months after the first line of treatment, is also a strong indicator of long-term survival, since 95% of the LTS patients in our study were sensitive to platinum-based treatments. If we consider that platinum sensitivity is correlated with the deficit of homologous recombination mediated mainly by BRCA 1 and 2, and also other genes arising in 51% of the cases, these genes can be expected to represent markers for LTS and to become a major surrogate factor for the prognostic assessment and help in adapting the subsequent appropriate treatment. In our study, as we had too-few patients with a known BRCA status, we were unable to show either a better prognosis \[[@B12-cancers-12-02184]\], as already demonstrated for mutated patients, or a higher frequency of mutated patients among the long-term survivors. Prospects include conducting a specific study to better characterize the biological factors that are predictive of platinum sensitivity, such as factors involved in homologous recombination, tumor microenvironment (PD-L1 status and immune infiltrate), or immunoreaction \[[@B39-cancers-12-02184]\], for which a first set of results will be soon available. Another limitation of the study is the relatively short follow-up time, considering the context and population studied.

4. Patients and Methods {#sec4-cancers-12-02184}
=======================

4.1. Database {#sec4dot1-cancers-12-02184}
-------------

The ovarian cancer database at our institution was created in 1995 and has been regularly implemented since then. It currently holds information on around 600 patients with high-grade epithelial ovarian cancer. For study purposes, the date of diagnosis; tumor histology; FIGO staging; peritoneal carcinomatosis index (PCI); detailed treatment data (primary or interval debulking surgery, residual macroscopic disease, neoadjuvant or adjuvant chemotherapy, type of chemotherapy, and number of cycles); BRCA 1 and 2 status; recurrence information; duration of treatment-free interval; and date of death or date and condition at the last follow-up were all recorded.

4.2. Study Patients {#sec4dot2-cancers-12-02184}
-------------------

Study data were extracted from the ovarian cancer database at our institution. All consecutive patients aged 18 or over, treated at our institution for FIGO stage III -IV HGSOC since 1995, were included. The study was conducted in accordance with Good Clinical Practices, the Helsinki Declaration and was approved by the Montpellier Cancer Institute Institutional Review Board (ID number ICM-CORT-2016-09). All patients gave their written, informed consent.

4.3. Treatment {#sec4dot3-cancers-12-02184}
--------------

Patients considered as eligible for primary debulking surgery were operated, then received 6 to 9 cycles of combined platinum-based chemotherapy in addition. Patients with extended disease who were not eligible for primary debulking surgery received 3 to 4 cycles of neoadjuvant chemotherapy and then underwent interval debulking surgery followed by 3 to 6 cycles of the same treatment. None of the patients received first-line treatments with bevacizumab, PARP inhibitors, or immunotherapy.

4.4. Statistical Considerations {#sec4dot4-cancers-12-02184}
-------------------------------

Descriptive analyses are reported with medians and ranges for continuous variables and frequencies and percentages for categorical variables. The patients' characteristics were compared using the Kruskal-Wallis or Wilcoxon tests for continuous variables, and the chi-square or Fisher's exact tests for categorical variables. The treatment-free interval (TFI) was defined as the time from the end date of the 1st chemotherapy to the start date of the 2nd chemotherapy and the progression-free interval (PFI) as the time from the start date of the 1st chemotherapy to the date of progression. Note that the TFI is missing for the patients who only received the 1st line of chemotherapy.

The primary endpoint was the OS, defined as the time from the date of diagnosis to the date of last contact or documented death from any cause. OS rates (and their 95% confidence intervals, 95% CI) were estimated using the Kaplan Meier method and the median follow-up using the reverse Kaplan-Meier method.

The conditional probability of survival (CPS) was the probability of surviving Y years after diagnosis when the patient had already survived X years (Y \> X). For example, to compute the 5-year CPS estimates for patients who had already survived 1 year, the 5-year OS rate was divided by the 1-year OS rate. Ninety-five percent CIs were estimated using a variation of the Greenwood formula \[[@B40-cancers-12-02184]\].

To identify prognostic factors for OS in LTS, the Landmark analysis approach was used. We focused on patients who had already survived at least 5 years after diagnosis. Patients who died or were censored before the Landmark time were excluded from analysis. The Cox proportional hazard model was then used to determine the prognostic factors for LTS. All significance tests were two-sided, and statistical significance was set at *p* \< 0.05. All analyses were conducted using Stata software version 13 (StataCorp LP, College Station, TX, USA).

5. Conclusions {#sec5-cancers-12-02184}
==============

In conclusion, to the best of our knowledge, this study based on a homogeneous population of HGSOC patients is the largest series used for a retrospective analysis. It confirms that CPS can provide relevant, encouraging clinical information about the remaining life expectancy of ovarian cancer patients who have already survived a certain period of time since the diagnosis.
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![Conditional probability of survival at 5 years (**a**) and conditional probability of survival for one additional year (**b**) according to the time of diagnosis](cancers-12-02184-g001){#cancers-12-02184-f001}

cancers-12-02184-t001_Table 1

###### 

Patients′ characteristics at baseline.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                          Non-Long Survivors *n* = 284   Long-Term Survivors\   Total\        *p*-Value                
                                                                          *n* = 120              *n* = 404                              
  ---------------------------------------- ------------------------------ ---------------------- ------------- ----------- ----- ------ -------
  **Age**                                                                                                                               

  Median (range)                           62 (20--89)                    57 (21--83)            61 (20--89)   \<0.001                  

  \<65                                     168                            59.2                   91            75.8        259   64.1   0.001

  ≥65                                      116                            40.8                   29            24.2        145   35.9   

  **WHO Performance status**                                                                                                            0.045

  0--1                                     227                            84.7                   98            92.5        325   86.9   

  2                                        41                             15.3                   8             7.5         49    13.1   

  Missing                                  16                                                    14                        30           

  **CA 125 level**                                                                                                                      

  Median (range)                           700 (6--21)                    790 (14--12)           734 (6--22)   0.360                    

  \<70                                     16                             7.5                    4             4.9         20    6.8    0.434

  ≥70                                      197                            92.5                   77            95.1        274   93.2   

  Missing                                  71                                                    39                        110          

  **FIGO stage**                                                                                                                        0.168

  III                                      230                            81.0                   104           86.7        334   82.7   

  IV                                       54                             19.0                   16            13.3        70    17.3   

  **Metastasis localization (*n* = 70)**                                                                                                

  Pleural                                  34                             69.4                   8             61.5        42    67.7   

  Visceral                                 15                             30.6                   5             38.5        20    32.3   

  Missing                                  5                                                     3                         8            

  N stage                                                                                                                               0.431

  N−                                       63                             28.0                   32            32.3        95    29.3   

  N+                                       162                            72.0                   67            67.7        229   70.7   

  Missing                                  59                                                    21                        80           

  **BRCA mutation**                                                                                                                     0.768

  Mutated BRCA1                            12                             20.7                   15            25.9        27    23.3   

  Mutated BRCA2                            5                              8.6                    6             10.3        11    9.5    

  No mutation                              41                             70.7                   37            63.8        78    67.2   

  Missing                                  226                                                   62                        288          
  ---------------------------------------------------------------------------------------------------------------------------------------------

WHO: World Health Organization, FIGO: Fédération Internationale de Gynécologie et d'Obstétrique, BRCA: breast cancer.

cancers-12-02184-t002_Table 2

###### 

Treatments.

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                             Non-Long Survivors\   Long-Term Survivors\   Total\              *p*-Value                 
                                              *n* = 284             *n* = 120              *n* = 404                                     
  ------------------------------------------- --------------------- ---------------------- ------------------- ----------- ----- ------- ---------
  **Surgery type**                                                                                                                       \<0.001

  Primary                                     133                   46.8                   81                  67.5        214   53.0    

  Interval surgery                            151                   53.2                   39                  32.5        190   47.0    

  **Digestive resection**                                                                                                                \<0.001

  0                                           87                    43.1                   66                  60.0        153   49.0    

  \>1                                         115                   56.9                   44                  40.0        159   51.0    

  Missing                                     82                                           10                              92            

  **Splenectomy**                                                                                                                        0.241

  No                                          128                   96.2                   75                  92.6        203   94.9    

  Yes                                         5                     3.8                    6                   7.4         11    5.1     

  Missing                                     151                                          39                              190           

  **Primary or interval surgery**                                                                                                        0.192

  Complete (Gross total resection)            160                   56.3                   76                  63.3        236   58.4    

  Incomplete (Macroscopic residual disease)   124                   43.7                   44                  36.7        168   41.6    

  **Initial PCI**                                                                                                                        

  Median (range)                              14 (0--33)            11 (0--24)             13 (0--33)          \<0.001                   

  \<17                                        165                   63.0                   87                  82.1        252   68.5    \<0.001

  ≥17                                         97                    37.0                   19                  17.9        116   31.5    

  Missing                                     22                                           14                              36            

  **Chemotherapy**                                                                                                                       

  Neoadjuvant CT                              147                   51.9                   37                  31.1        184   45.8    \<0.001

  Missing                                     1                                            1                               2             

  **1st CT line regimen**                                                                                                                0.793

  Platinum salts/Paclitaxel                   223                   79.7                   97                  82.2        320   80.4    

  Platinum salts/Exoxan                       30                    10.7                   12                  10.2        42    10.6    

  Others                                      27                    9.6                    9                   7.6         36    9.0     

  Missing                                     4                                            2                               6             

  **Number of cycles**                                                                                                                   0.946

  Median (range)                              6 (1--14)             6 (3--12)              6 (1--14)                                     

  Missing                                     6                                            1                               7             

  **Sensibility to 1st CT line**                                                                                                 0.001   

  Refractory/Resistant                        85                    31.8                   6                   5.0         91    23.5    

  Sensible                                    181                   68.2                   114                 95.0        295   76.5    

  Missing                                     18                                           0                               18            

  **Treatment-free Interval (months)**                                                     \<0.001                                       

  Median (range)                              8.5 (0.4--47.2)       23.9 (0.7--121.6)      11 (0.4--121.6)                               

  \<18                                        149                   85.6                   35                  42.2        184   71.6    

  ≥18                                         25                    14.4                   48                  57.8        73    28.4    

  Missing/No 2nd CT line                      110                                          37                              147           

  **Progression-free Interval (months)**                                                   \<0.001                                       

  Median (range)                              14.5 (0.4--56.6)      43.4 (2.3--248.2)      17.4 (0.4--248.2)                             

  \<18                                        187                   66.6                   17                  14.2        204   50.9    

  ≥18                                         94                    33.5                   103                 85.8        197   49.1    

  Missing                                     3                                            0                               3             
  ------------------------------------------------------------------------------------------------------------------------------------------------

PCI: peritoneal carcinomatosis index. CT: chemotherapy.

cancers-12-02184-t003_Table 3

###### 

Overall survival rates (left) and conditional probabilities of survival (right) depending on the survived time interval.

  *n* = 404                                                                                                        
  ----------- ------ -------------- ----- ------ -------------- ------ -------------- ------ -------------- ------ --------------
  1 year      95.0   (92.4; 96.7)   373   84.0   (80.2; 87.8)   68.9   (64.0; 73.8)   52.4   (46.9; 57.8)   42.8   (37.3; 48.3)
  2 years     79.8   (75.4; 83.5)   279                         82.0   (77.4; 86.6)   62.3   (56.5; 68.2)   50.9   (44.8; 57.0)
  3 years     65.5   (60.3; 70.1)   219                                               76.0   (70.2; 81.7)   62.0   (55.4; 68.7)
  4 years     49.7   (44.3; 54.9)   158                                                                     81.7   (75.5; 87.8)
  5 years     40.6   (35.3; 45.9)   120                                                                            

cancers-12-02184-t004_Table 4

###### 

Prognostic factors of long survival in univariate and multivariate analyses.

  *n* = 120                     Univariate Analysis   Multivariate Analysis          
  ----------------------------- --------------------- ----------------------- ------ ----------------
  **Age**                                                                            
  \<65                          1                                                    
  ≥65                           1.60                  (0.95; 2.70)                   
                                *p* = 0.085                                          
  **WHO Performance status**                                                         
  0                             1                                                    
  1--2                          1.15                  (0.42; 3.18)                   
                                *p* = 0.790                                          
  **FIGO stage**                                                                     
  III                           1                                                    
  IV                            1.08                  (0.53; 2.19)                   
                                *p* = 0.830                                          
  N stage                                                                            
  N−                            1                                                    
  N+                            1.33                  (0.75; 2.38)                   
                                *p* = 0.325                                          
  BRCA mutation                                                                      
  Mutated BRCA1/2               1                                                    
  No mutation                   1.02                  (0.43; 2.44)                   
                                *p* = 0.958                                          
  Primary or interval surgery                                                        
  Complete                      1                                                    
  Incomplete                    1.92                  (1.17; 3.14)                   
                                *p* = 0.011                                          
  Initial PCI                                                                        
  \<17                          1                                                    
  ≥17                           1.78                  (0.96; 3.27)                   
                                *p* = 0.079                                          
  Sensibility to 1st CT line                                                         
  Refractory/Resistant          1                                                    
  Sensitive                     0.47                  (0.19; 1.19)                   
                                *p* = 0.149                                          
  Progression-free interval                                                          
  \<18 months                   1                                             1      
  ≥18 months                    0.23                  (0.13; 0.40)            0.23   \[0.13; 0.40\]
                                *p* \< 0.0001         *p* \< 0.0001                  

HR: hazard ratio, 95% CI: 95% confidence interval, WHO: World Health Organization, FIGO: Fédération Internationale de Gynécologie et d'Obstétrique, BRCA1: breast cancer 1, PCI: peritoneal carcinomatosis index, and CT: chemotherapy.
